Claire Julian-Reynier1, Noémie Resseguier2, Anne-Deborah Bouhnik2, François Eisinger1, Christine Lasset3, Emmanuelle Fourme4, Catherine Noguès4. 1. 1] Institut Paoli-Calmettes, UMR912, Marseille, France [2] INSERM, UMR912, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, France [3] Aix-Marseille University, UMR_S912, IRD, Marseille, France. 2. 1] INSERM, UMR912, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, France [2] Aix-Marseille University, UMR_S912, IRD, Marseille, France. 3. Centre Léon Bérard, Lyon, France. 4. 1] Hôpital René Huguenin, Saint Cloud, France [2] Institut Curie, Paris, France.
Abstract
PURPOSE: This study aimed to measure patients' smoking patterns for 5 years after BRCA1/2 test result disclosure. METHODS: A national cohort consisting of 621 French cancer-free women from families with BRCA1/2 mutations (mean age (SD): 40.5 years (11.5 years)) were included from December 1999 to January 2006, before disclosure of genetic test results, and followed for 5 years. They completed self-administered questionnaires about their cigarette smoking behaviors before receiving their test results (baseline) and 6, 12, 24, and 60 months after disclosure. Multivariate statistical analyses of the changes in participants' smoking behaviors were performed using a zero-inflated Poisson mixed model. RESULTS: Baseline smoking was found to depend on age, educational level, marital status, alcohol consumption, body mass index, and cancer risk perception. The zero-inflated part of the model showed the occurrence of no significant changes in the percentage of smokers during the 5 years after disclosure of the BRCA1/2 test results; however, daily smoking among BRCA1/2 carriers decreased significantly compared with that of noncarriers (adjusted hazard ratio = 0.83; (95% confidence interval: 0.69-0.99); P = 0.04) after adjusting for baseline smoking behavior. CONCLUSION: It would be worth investigating the possibility of counseling women during the genetic testing process about the multiple risk factors involved in cancer, such as genetic and lifestyle factors.
PURPOSE: This study aimed to measure patients' smoking patterns for 5 years after BRCA1/2 test result disclosure. METHODS: A national cohort consisting of 621 French cancer-free women from families with BRCA1/2 mutations (mean age (SD): 40.5 years (11.5 years)) were included from December 1999 to January 2006, before disclosure of genetic test results, and followed for 5 years. They completed self-administered questionnaires about their cigarette smoking behaviors before receiving their test results (baseline) and 6, 12, 24, and 60 months after disclosure. Multivariate statistical analyses of the changes in participants' smoking behaviors were performed using a zero-inflated Poisson mixed model. RESULTS: Baseline smoking was found to depend on age, educational level, marital status, alcohol consumption, body mass index, and cancer risk perception. The zero-inflated part of the model showed the occurrence of no significant changes in the percentage of smokers during the 5 years after disclosure of the BRCA1/2 test results; however, daily smoking among BRCA1/2 carriers decreased significantly compared with that of noncarriers (adjusted hazard ratio = 0.83; (95% confidence interval: 0.69-0.99); P = 0.04) after adjusting for baseline smoking behavior. CONCLUSION: It would be worth investigating the possibility of counseling women during the genetic testing process about the multiple risk factors involved in cancer, such as genetic and lifestyle factors.
Authors: Steven S Fu; Michelle van Ryn; Scott E Sherman; Diana J Burgess; Siamak Noorbaloochi; Barbara Clothier; Brent C Taylor; Carolyn M Schlede; Randy S Burke; Anne M Joseph Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Karen M Emmons; Colleen M McBride; Elaine Puleo; Kathryn I Pollak; Elizabeth Clipp; Karen Kuntz; Bess H Marcus; Melissa Napolitano; Jane Onken; Frank Farraye; Robert Fletcher Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Colleen M McBride; Elaine Puleo; Kathryn I Pollak; Elizabeth C Clipp; Sam Woolford; Karen M Emmons Journal: Soc Sci Med Date: 2007-11-26 Impact factor: 4.634
Authors: Angela R Bradbury; Comfort N Ibe; James J Dignam; Shelly A Cummings; Marion Verp; Melody A White; Grazia Artioli; Laura Dudlicek; Olufunmilayo I Olopade Journal: Genet Med Date: 2008-03 Impact factor: 8.822
Authors: Joanne Soo-Min Kim; Peter C Coyte; Michelle Cotterchio; Louise A Keogh; Louisa B Flander; Clara Gaff; Audrey Laporte Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-15 Impact factor: 4.254